IL1RAP Knockout A549 Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Lung
Disease:
Lung adenocarcinoma

Datasheet

The IL1RAP Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in A-549 lung adenocarcinoma cells, designed to eliminate expression of the IL1RAP co-receptor. IL1RAP partners with IL1R1 to propagate signals from IL-1 family cytokines (IL-1??, IL-1??, IL-33, IL-36) via MyD88, IRAK1/4, and NF-??B/MAPK cascades, leading to pro-inflammatory and tumor-promoting gene expression. This knockout model enables dissection of IL-1/IL-33-driven inflammatory responses, downstream target regulation (e.g., IL-6, IL-8, TNF-??), and pathway interrogation in lung cancer biology. Typical applications include IL-1?? stimulation assays, phospho-NF-??B western blotting, RT-qPCR, ELISA, and drug screening for IL1RAP-targeted therapies.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

A549

Sex of Donor

Male

Age

58 years

Derived From Site

Lung

Gene Name

Il1rap

Gene Identifier

NCBI Gene ID 3556

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

MEM

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

IL1RAP Knockout A-549 Polyclonal Cells are a genetically engineered, CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line.

This product consists of a heterogeneous pool of cells carrying targeted disruption of the IL1RAP gene, avoiding clonal selection to maintain population-level diversity.

The polyclonal format reflects a CRISPR/Cas9-mediated gene ablation approach that introduces loss-of-function mutations across the IL1RAP locus, generating a stable knockout model without claims of monoclonality or defined biallelic modifications.

The cells are intended for functional studies requiring abrogation of IL1RAP-dependent signaling, providing a flexible tool for both general pathway analysis and targeted screening applications.